SHIELD

Medical implants have revolutionised healthcare by improving quality of life through replacing missing structures, restoring function, and promoting tissue regeneration. However, implant-associated infections (IAIs) undermine these benefits, particularly in orthopaedics, otology, and odontology, leading to chronic issues and substantial healthcare costs. IAIs, exacerbated by biofilm formation and antimicrobial resistance, pose a significant public health challenge. The SHIELD doctoral network aims to advance our understanding of IAIs, from their multifactorial pathogenesis to the development of new antibacterial biomaterials, bridging the gap between basic research and practical applications. SHIELD is structured around three scientific pillars to advance IAI control strategies in orthopaedics, otology, and odontology: regenerative medicine, biomaterial science, and translational research models. These pillars drive research on therapeutic strategies, innovative biomaterials, and experimental proof-of-concept models. The network focuses on clinical studies, antimicrobial strategies for implants, and preclinical models to study IAI mechanisms. Our goal is to train 16 young researchers through an interdisciplinary and translational approach, combining basic research with preclinical and clinical testing. In collaboration with 27 partners from 11 countries, SHIELD brings together expertise from multiple disciplines to bridge the gap between research and real-world applications. By developing new antimicrobial solutions for implants and conducting bench-to-bedside research, SHIELD aims to improve infection management protocols and patient care, significantly advancing the field of infection control in medical devices.